Francis Collins and Anthony Fauci, formerly the directors of the National Institutes for Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), respectively, reportedly received at least 58 royalty payments from businesses licensing their inventions. These creations were funded by taxpayer money, as recently disclosed records from renowned transparency watchdog OpenTheBooks illustrate.
These documents shed light on which companies compensated NIH scientists for specific inventions and the timing of these transactions. Resulting from a Freedom of Information Act clash with the NIH, the revelation sums up a whopping $325 million from 56,000 transactions. However, the individual amounts tied to each payment remain undisclosed.
Fauci accumulated 37 payments spanning 2010-2021 from three corporate entities: Santa Cruz Biotechnology (15 payments); Ancell Corp (14 payments); and Chiron Corp (8 payments), the latter of which was purchased by pharmaceutical giant Novartis in 2006.
Collins received 21 payments between 2010-2018. GeneDx, a genetic research firm with a history of federal contracts from NIH, was the primary contributor, making 12 payments. Other contributors include Quest Diagnostics’ Specialty Laboratories, Ionis Pharmaceuticals, and the Progeria Research Foundation.
These unearthed documents run contrary to Fauci’s past assertions to Sen. Rand Paul (R-KY), in which Fauci claimed it was doubtful that he received royalties from NIAID-funded entities.
Previously, Fauci, during his term as NIAID director, accepted over $45,000 in royalties for an AIDS treatment project funded by NIH. However, later studies showed that the research had zero efficacy, and Fauci has never provided proof backing his claim that the royalties were donated to charity.